4D Molecular’s Senior Director Secures Zero‑Cost Options Amid Investor Buzz and Uncertain Earnings Outlook
Senior director SBLENDORIO GLENN’s 45,000‑share option award at 4D Molecular signals long‑term confidence in the biotech’s pipeline, but investors should watch clinical milestones before betting on potential upside.
- 4D Molecular Therapeutics Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read